Israel’s Teva reported success in a Phase III clinical trial for its abuse-deterrent extended-release CEP-33237 treatment for chronic low back pain. The results showed significant improvement as measured by both weekly average Worst Pain Intensity and weekly Average Pain Intensity scores.
http://www.globes.co.il/en/article-teva-reports-success-in-back-pain-treatment-study-1000935409